弥漫性胸膜间皮瘤多学科联合诊断进展及临床意义  

Progress in pathological diagnosis and clinical significance of diffuse pleural mesothelioma

作　　者：余科科 张杰[1] 赵珩[3] Yu Keke;Zhang Jie;Zhao Heng(Department of Pathology,Shanghai Jiaotong University,School of Medicine,Shanghai Chest Hospital,Shanghai 200030,China;Department of Biobank,Shanghai Jiaotong University,School of Medicine,Shanghai Chest Hospital,Shanghai 200030,China;Department of Thoracic Surgery,Shanghai Jiaotong University,School of Medicine,Shanghai Chest Hospital,Shanghai 200030,China)

机构地区：[1]上海交通大学医学院附属胸科医院、上海市胸科医院病理科,上海200030 [2]上海交通大学医学院附属胸科医院、上海市胸科医院生物样本库,上海200030 [3]上海交通大学医学院附属胸科医院、上海市胸科医院胸外科,上海200030

出　　处：《中华胸心血管外科杂志》2023年第2期124-128,共5页Chinese Journal of Thoracic and Cardiovascular Surgery

摘　　要：弥漫性胸膜间皮瘤是一种恶性间皮细胞肿瘤,表现为胸膜或心包的弥漫性受累,肿瘤侵袭性强、恶性度高、预后差。弥漫性胸膜间皮瘤起病隐匿,初诊时多为晚期,治疗困难,疗效欠佳,5年生存率约10%,中位生存期7~9个月。精准的病理诊断和预后分析对于患者选择最合适的治疗方式非常重要。本文综述国内、外弥漫性胸膜间皮瘤的多学科联合诊断进展及其临床意义,以期有助于提高临床规范化诊疗水平。Diffuse pleural mesothelioma is a malignant mesothelioma,which is characterized by diffuse involvement of pleura or pericardium,strong invasion,high malignancy and poor prognosis.The onset of diffuse pleural mesothelioma is concealed.Most of them are in the late stage at the initial diagnosis.The treatment is difficult and the curative effect is poor.The 5-year survival rate is about 10%,and the median survival time is 7 to 9 months 1.Accurate pathological diagnosis and prognosis analysis are very important for patients to choose the most appropriate treatment.Therefore,it is urgent to make a fuller understanding of diffuse pleural mesothelioma on the basis of existing pathological research and clinical research evidence,so as to improve the level of standardized clinical diagnosis and treatment.

关 键 词：诊断进展 弥漫性胸膜间皮瘤 多学科联合 恶性度 间皮细胞 肿瘤侵袭性 预后差 诊断和预后 

分 类 号：R734.3[医药卫生—肿瘤]